A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
Latest Information Update: 19 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-355; MK-3475-355/KEYNOTE-355
- Sponsors Merck Sharp & Dohme Corp.
- 19 Sep 2024 This trial has been completed in Spain (Global end date: 2023-10-30) according to European Clinical Trials Database record.
- 11 Feb 2024 This trial has been Completed in Ireland, According to European Clinical Trials Database record.
- 07 Feb 2024 This trial has been Completed in German, According to European Clinical Trials Database record.